!"#$%&'()*+$,*-&$).&/#+""0")*-& 12034(&5$0$)(& 6$+*)"+&& 78&'29"&:)*"+)$;()$%&& & & !"#$%&"'()*+,"-.)./,"
8(<3,-& 0"1/2,34,3.5/6"."2,)4./7" 0"8,99.:,3.5,/"2,/;3.2;<"./=".63>>)>/;<" 0"?*2>/<*/6"@63>>)>/;" 0"A>7";>3)<" " " " " " !"#$%&"'()*+,"-.)./,"
:))(=$;()& >$)$#"0")*& 8",?)(%(#@& :6&& '(00"+,3$%3B$;()& :)*"%%",*2$%&6+(<"+*@&& A2-3)"--& !"#$%&"'()*+,"-.)./,"
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
!"#$%&:--2"-&&& M"%$*".&*(&$&G*$+*Y2<&'(0<$)@& • @3529>",B"1/2,34,3.5,/" • C(<*/><<"D.)>"E>6*<;3.5,/"F,3)" • G,).*/"D.)>"8>35H2.;>" • C(<*/><<"?*2>/<>"./="I>3)*;" • J)49,7)>/;"@63>>)>/;" • I.3;/>3<K*4"@63>>)>/;" • I3,;>25,/",B"1I"L4.;>/;<M2,473*6K;MNOM1/=(<;3*.9"G><*6/M I9./;"P.3*>;7Q" • 8,99.:,3.5,/"@63>>)>/;<"L>R6R"ESG"8,99.:,3.5,/" 8,/;3.2;<T"?*2>/<*/6"@63>>)>/;"">;2RQ" • N>2K/*2.9"3>6(9.5,/<"./="<;./=.3=<" • J/B,32>)>/;MG*<4(;>"<>U9>)>/;" !"#$%&"'()*+,"-.)./,"
IP Commercialization " • Sales of IP (Acquisition) • Licensing • Start-up and Spin-off 6/87[8& 87'5[\!\_1&G/!7G& MZJ& '\>>7M':/!:]/8:\[& &/66!:'/8:\[& !:'7[G:[_& G8/M8Y`6G& 'M7/8:\[& 6M\87'8:\[& 7^6!\:8/8:\[& !"#$%&"'()*+,"-.)./,"
!"#$%%@&9(2).&'()*+$,*-&$).& /#+""0")*-&&C(+&& MZJ&'(%%$9(+$;()&$).&8",?)(%(#@&& '(00"+,3$%3B$;()& & • 8,/;3.2;"3><>.32K".63>>)>/;" • 8,99.:,3.5V>"3><>.32K".63>>)>/;" • 8,/<(95/6M+/,W"K,W"@63>>)>/;" • O.;>3*.9";3./<B>3".63>>)>/;"LON@Q" • 8,/H=>/5.9*;7".63>>)>/;"LDG@Q" • I.352*4.5,/".63>>)>/;" • ?*2>/<*/6".63>>)>/;" !"#$%&"'()*+,"-.)./,"
[()&J3-,%(-2+"&/#+""0")*&T[J/U& • @9<,"2.99>=".<" “ 2,/H=>/5.9*;7".63>>)>/; ” " • @/7"*/B,3).5,/"=*<29,<>=";,"./,;K>3"4.3;7" • DG@<"43>V>/;";K*3="4.35><"B3,)"(<*/6";K>"*/B,3).5,/" =*<29,<>="W*;K,(;";K>"4>3)*<<*,/" • DG@<".3>",X>/">Y2K./6>=":>B,3>"9*2>/<*/6"/>6,5.5,/" • 8,)4./*><",X>/"3>Z(><;"3><>.32K>3<";,"<*6/"DG@<":>B,3>" >/;>3*/6"3><>.32K"2,/;3.2;<" !"#$%&"'()*+,"-.)./,"
[()&J3-,%(-2+"&/#+""0")*&T[J/U& DG@"43,V*<*,/<"*/29(=>[" " • 1=>/5H2.5,/",B"4.35><" • 1=>/5H2.5,/",B"2,/H=>/5.9"*/B,3).5,/" • G>H/*5,/",B"4(34,<><"B,3"WK*2K"*/B,3).5,/"2./":>"(<>=" • JR6RT"<,9>97"B,3"4(34,<><",B">V.9(.5/6"."9*2>/<*/6" ,44,3;(/*;7" • E>Z(*3>)>/;<"B,3"3>;(3/M=><;3(25,/",B"2,/H=>/5.9" */B,3).5,/" " !"#$%&"'()*+,"-.)./,"
[()&J3-,%(-2+"&/#+""0")*&T[J/U& DG@"=,><"/,;".4497";,[" " • 1/B,3).5,/"*/";K>"4(:9*2"=,).*/" • 1/B,3).5,/".93>.=7"4,<<><<>=":7";K>"3>2*4*>/;" • 1/B,3).5,/"=*<29,<>=";,";K>"3>2*4*>/;";K3,(6K" 9>6*5).;>")>./<" !"#$%&"'()*+,"-.)./,"
>$*"+3$%&8+$)-C"+&/#+""0")*&T>8/U& • Contracts that govern the transfer of physical assets, • Typically biological materials (reagents, cell lines, plasmids, and vectors) that are transferred for the purpose of research or commercialization • Chemical compounds • MTA ensure transfer of possession but not legal title !"#$%&"'()*+,"-.)./,"
[(&M"="+-"&")#3)""+3)#&'%$2-"& • Prohibits the recipient of confidential information/material from using the information to develop a similar product. • The clause is often included in a NDA/MTA/License Agreement • Commonly used when the disclosed information is source code, product designs or other designs. “No Reverse Engineering: Recipient shall not analyze, decompile, or reverse engineer or cause a third party to analyze, decompile or reverse engineer any Confidential Information for any purpose”. !"#$%&"'()*+,"-.)./,"
IP Licensing " " \ @"3,(;>",B"2,))>32*.9*].5,/"WK>3>"./"1I"3*6K;<"K,9=>3"6*V><" ./,;K>3">/5;7";K>".(;K,3*;7";,">Y49,*;T").+>T"K.V>").=>T"(<>T" <>99T"2,47T"=*<49.7T"=*<;3*:(;>T"),=*B7T">;2R";K>"1I"0"*/"3>;(3/T" ;K>"9*2>/<>>"W*99"4.7"3,7.95><" " \ NK>"),<;"4,4(9.3"./="<(<;.*/.:9>"W.7",B"2,))>32*.9*]*/6"1IE" " \ ^K.3*/6":(<*/><<"3*<+<" \ O./.6>=";K3,(6K"W3*U>/"9>6.997":,(/=".63>>)>/;<" " \ @63>>)>/;<"<54(9.;>"=>;.*9<",B">Y;>/;",B"3*6K;<",B">Y49,*;.5,/" !"#$%&"'()*+,"-.)./,"
!3,")-3)#&/#+""0")*& • G>H/><";K.;"WK.;"9*2>/<,3"./="9*2>/<>>".63>>=";,"9*2>/<>"" • G>H/><"WK.;"7,(".99,W";K>"9*2>/<>>";,"=,"W*;K"*;"./=" WK.;"9>6.9"3*6K;<":,;K"4.35><"K.V>" • F*/./2*.9"./="4.7)>/;"2,/=*5,/<" • ?*2>/<*/6"8,/=*5,/<"" • NK>"9*2>/<,3 ’ <",:9*6.5,/<" • _:9*6.5,/<"2,)),/";,":,;K"4.35><" !"#$%&"'()*+,"-.)./,"
Key Terms and Conditions G29a",*&0$b"+&& • G,(<"&(C&*?"&%3,")-"& • R3"%.&(C&2-"&& • \D)"+-?3<& • '()c.");$%3*@& • 7d,%2-3="&(+&)()Y"d,%2-3="& • G29Y%3,")-3)#& • 8"++3*(+@&& • J2+$;()&R3)$),3$%&*"+0-&& • J"="%(<0")*&+3#?*-& • J"+3=$;="&D(+4-E&30<+(="0")*-& • R2*2+"&="+-3()&(C&*?"&*",?)(%(#@& • e$++$);"-&& • J3-<2*"&-"b%"0")*& • !"#$%&"'()*+,"-.)./,"
Recommend
More recommend